Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open‐Label, Maximal‐Use Systemic Exposure Study

ConclusionsThis open‐label study provides evidence that crisaborole topical ointment, 2% was well tolerated, with limited systemic exposure under maximal‐use conditions in patients ages 2 years and older.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fpde.12872

Source: Pediatric Dermatology - April 30, 2016 Category: Dermatology Authors: Lee T. Zane, Leon Kircik, Robert Call, Eduardo Tschen, Zoe Diana Draelos, Sanjay Chanda, Merrie Van Syoc, Adelaide A. Hebert Tags: Original Article Source Type: research